Joseph R. Garlich

1.3k total citations
33 papers, 1.1k citations indexed

About

Joseph R. Garlich is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Joseph R. Garlich has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Joseph R. Garlich's work include PI3K/AKT/mTOR signaling in cancer (10 papers), Protein Degradation and Inhibitors (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Joseph R. Garlich is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (10 papers), Protein Degradation and Inhibitors (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Joseph R. Garlich collaborates with scholars based in United States, Canada and India. Joseph R. Garlich's co-authors include Donald L. Durden, Raymond J. Bergeron, Shweta Joshi, Alok R. Singh, Guillermo A. Morales, Pradip De, Nandini Dey, Qiong Peng, Jing Su and Gordon B. Mills and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Joseph R. Garlich

33 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph R. Garlich United States	17	735	210	140	140	131	33	1.1k
Luisa Rusconi Italy	16	855 1.2×	426 2.0×	84 0.6×	96 0.7×	162 1.2×	32	1.3k
Jong Sung Koh South Korea	17	542 0.7×	196 0.9×	58 0.4×	63 0.5×	284 2.2×	36	923
Günter Krause Germany	17	793 1.1×	152 0.7×	212 1.5×	121 0.9×	67 0.5×	45	1.3k
Murray J. Towle United States	17	440 0.6×	509 2.4×	76 0.5×	59 0.4×	211 1.6×	24	1.1k
Paul Tapang United States	14	444 0.6×	236 1.1×	58 0.4×	149 1.1×	143 1.1×	29	773
Linda Kessler United States	14	746 1.0×	352 1.7×	62 0.4×	48 0.3×	137 1.0×	38	1.1k
Bibiana I. Ferreira Portugal	17	633 0.9×	108 0.5×	89 0.6×	83 0.6×	69 0.5×	34	965
Rooha Contractor United States	14	870 1.2×	469 2.2×	93 0.7×	92 0.7×	214 1.6×	24	1.3k
Zi-Jie Long China	23	797 1.1×	387 1.8×	71 0.5×	225 1.6×	120 0.9×	29	1.4k
Andrew G. Bosanquet United Kingdom	18	382 0.5×	303 1.4×	241 1.7×	164 1.2×	51 0.4×	45	974

Countries citing papers authored by Joseph R. Garlich

Since Specialization

Citations

This map shows the geographic impact of Joseph R. Garlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph R. Garlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph R. Garlich more than expected).

Fields of papers citing papers by Joseph R. Garlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph R. Garlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph R. Garlich. The network helps show where Joseph R. Garlich may publish in the future.

Co-authorship network of co-authors of Joseph R. Garlich

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph R. Garlich. A scholar is included among the top collaborators of Joseph R. Garlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph R. Garlich. Joseph R. Garlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joshi, Shweta, Kevin X. Liu, Muamera Zulcic, et al.. (2020). Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 19(3). 755–764. 28 indexed citations

Joshi, Shweta, Alok R. Singh, Kevin X. Liu, et al.. (2019). SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Molecular Cancer Therapeutics. 18(6). 1036–1044. 41 indexed citations

Andrews, Forest H., Alok R. Singh, Shweta Joshi, et al.. (2017). Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proceedings of the National Academy of Sciences. 114(7). E1072–E1080. 98 indexed citations

Singh, Alok R., Shweta Joshi, Adam M. Burgoyne, et al.. (2016). Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 15(11). 2553–2562. 51 indexed citations

Singh, Alok R., Shweta Joshi, Muamera Zulcic, et al.. (2016). PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS ONE. 11(3). e0150836–e0150836. 23 indexed citations

Singh, Alok R., Shweta Joshi, Joseph R. Garlich, Guillermo Morales, & Donald L. Durden. (2015). Abstract A27: Dual PI3K/BRD4 (kinase/epigenetic) inhibitors for maximal MYC control in cancer therapeutics. Molecular Cancer Therapeutics. 14(7_Supplement). A27–A27. 2 indexed citations

De, Pradip, Nandini Dey, P. Leif Bergsagel, et al.. (2013). An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemotherapy and Pharmacology. 71(4). 867–881. 21 indexed citations

Mahadevan, Daruka, E. Gabriela Chiorean, Daniel D. Von Hoff, et al.. (2011). Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.. Journal of Clinical Oncology. 29(15_suppl). 3015–3015. 10 indexed citations

Garlich, Joseph R., et al.. (2011). Abstract LB-383: Translational studies of the novel prodrug PI3K/mTOR/PIM1 inhibitor SF1126 in DLBCL. Cancer Research. 71(8_Supplement). LB–383. 1 indexed citations

10.

Garlich, Joseph R., Candace Shelton, Wenqing Qi, et al.. (2010). Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.. Blood. 116(21). 1783–1783. 8 indexed citations

11.

Lonial, Sagar, R. Donald Harvey, Dixil Francis, et al.. (2009). Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.. Blood. 114(22). 3879–3879. 5 indexed citations

12.

David, Ebenezer, Sagar Lonial, Benjamin G. Barwick, et al.. (2009). B358 SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen. Clinical Lymphoma & Myeloma. 9. S127–S127. 1 indexed citations

13.

Garlich, Joseph R., Pradip De, Nandini Dey, et al.. (2008). A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. Cancer Research. 68(1). 206–215. 230 indexed citations

14.

Chiorean, E. Gabriela, Mitesh J. Borad, Daniel D. Von Hoff, et al.. (2008). Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3- kinase (PI3K) inhibitor in patients with solid tumors. Journal of Clinical Oncology. 26(15_suppl). 14532–14532. 12 indexed citations

15.

Peng, Qiong, Pradip De, Nandini Dey, Joseph R. Garlich, & Donald L. Durden. (2007). Preclinical studies of a pan PI3K inhibitor (SF1126) in renal cell carcinoma. Cancer Research. 67. 2378–2378. 1 indexed citations

16.

Crouse, Gary D., Thomas C. Sparks, James Gifford, et al.. (2001). Recent advances in the chemistry of spinosyns. Pest Management Science. 57(2). 177–185. 73 indexed citations

17.

Volkert, Wynn A., et al.. (1991). Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 18(2). 235–240. 9 indexed citations

18.

Bergeron, Raymond J., Joseph R. Garlich, & James S. McManis. (1985). Total synthesis of vibriobactin. Tetrahedron. 41(3). 507–510. 24 indexed citations

19.

Bergeron, Raymond J., Joseph R. Garlich, & Neal J. Stolowich. (1984). Reagents for the stepwise functionalization of spermidine, homospermidine, and bis(3-aminopropyl)amine. The Journal of Organic Chemistry. 49(16). 2997–3001. 53 indexed citations

20.

Kaiser, Edwin M., William R. Thomas, James R. McClure, et al.. (1981). Regiointegrity of carbanions derived by selective metalations of dimethylpyridines and -quinolines. Journal of Organometallic Chemistry. 213(2). 405–417. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact